622.9K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 5.79 per share. | 28 Jan 2025 | 708 | 166,390 (0%) | 0% | 5.8 | 4,099 | Common Stock |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 5.79 per share. | 28 Jan 2025 | 519 | 123,367 (0%) | 0% | 5.8 | 3,005 | Common Stock |
| Aaron Tachibana L. | CFO AND COO | Sale of securities on an exchange or to another person at price $ 3.82 per share. | 16 Dec 2024 | 6,865 | 167,098 (0%) | 0% | 3.8 | 26,224 | Common Stock |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 3.82 per share. | 16 Dec 2024 | 4,834 | 123,886 (0%) | 0% | 3.8 | 18,466 | Common Stock |
| M. Stephen Moore | SVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.82 per share. | 16 Dec 2024 | 1,513 | 65,875 (0%) | 0% | 3.8 | 5,780 | Common Stock |
| Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 3.79 per share. | 18 Nov 2024 | 1,307 | 173,963 (0%) | 0% | 3.8 | 4,954 | Common Stock |
| Stephen M. Moore | SVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.79 per share. | 18 Nov 2024 | 1,693 | 67,388 (0%) | 0% | 3.8 | 6,416 | Common Stock |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 3.79 per share. | 18 Nov 2024 | 921 | 128,720 (0%) | 0% | 3.8 | 3,491 | Common Stock |
| Christopher Hall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 5.38 per share. | 01 Nov 2024 | 26,443 | 178,098 (0%) | 0% | 5.4 | 142,263 | Common Stock |
| Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 30 Jul 2024 | 742 | 175,270 (0%) | 0% | 3.0 | 2,204 | Common Stock |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 30 Jul 2024 | 524 | 127,227 (0%) | 0% | 3.0 | 1,556 | Common Stock |
| Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 17 Jun 2024 | 7,176 | 176,012 (0%) | 0% | 1.3 | 9,257 | Common Stock |
| Stephen M. Moore | SVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 17 Jun 2024 | 1,585 | 69,081 (0%) | 0% | 1.3 | 2,045 | Common Stock |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 17 Jun 2024 | 5,055 | 127,751 (0%) | 0% | 1.3 | 6,521 | Common Stock |
| Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 17 May 2024 | 1,333 | 183,188 (0%) | 0% | 1.4 | 1,840 | Common Stock |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Lonnie Shoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | SVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 17 May 2024 | 1,731 | 70,666 (0%) | 0% | 1.4 | 2,389 | Common Stock |
| Kenneth J. Widder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 17 May 2024 | 940 | 132,806 (0%) | 0% | 1.4 | 1,297 | Common Stock |
| Stephen M. Moore | SVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 30 Apr 2024 | 4,523 | 72,397 (0%) | 0% | 1.4 | 6,197 | Common Stock |
| Aaron L. Tachibana | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Christopher Hall | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Richard Chen | CHIEF MEDICAL OFFICER AND EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Woodrow A. Myers | Director | Purchase of securities on an exchange or from another person at price $ 1.67 per share. | 01 Mar 2024 | 10,000 | 26,116 (0%) | 0% | 1.7 | 16,700 | Common Stock |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 29 Jan 2024 | 526 | 128,870 (0%) | 0% | 1.4 | 721 | Common Stock |
| Tachibana L. Aaron | CFO AND COO | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 29 Jan 2024 | 716 | 184,521 (0%) | 0% | 1.4 | 981 | Common Stock |
| Aaron Tachibana L. | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 15 Dec 2023 | 6,747 | 185,237 (0%) | 0% | 1.5 | 9,918 | Common Stock |
| Moore Stephen M. | General Counsel | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 15 Dec 2023 | 1,476 | 76,920 (0%) | 0% | 1.5 | 2,170 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 15 Dec 2023 | 4,708 | 129,396 (0%) | 0% | 1.5 | 6,921 | Common Stock |
| Aaron L. Tachibana | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 16 Nov 2023 | 1,344 | 191,984 (0%) | 0% | 1.0 | 1,398 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 16 Nov 2023 | 1,722 | 78,396 (0%) | 0% | 1.0 | 1,791 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 16 Nov 2023 | 940 | 124,104 (0%) | 0% | 1.0 | 978 | Common Stock |
| Christopher Hall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 01 Nov 2023 | 20,459 | 204,541 (0%) | 0% | 0.9 | 19,027 | Common Stock |
| Aaron L. Tachibana | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.26 per share. | 31 Jul 2023 | 662 | 193,328 (0%) | 0% | 2.3 | 1,496 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 2.26 per share. | 31 Jul 2023 | 485 | 125,044 (0%) | 0% | 2.3 | 1,096 | Common Stock |
| Aaron L. Tachibana | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.07 per share. | 16 Jun 2023 | 6,904 | 193,990 (0%) | 0% | 2.1 | 14,291 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 2.07 per share. | 16 Jun 2023 | 1,509 | 80,118 (0%) | 0% | 2.1 | 3,124 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 2.07 per share. | 16 Jun 2023 | 4,817 | 125,529 (0%) | 0% | 2.1 | 9,971 | Common Stock |
| Kenneth J. Widder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Aaron L. Tachibana | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 17 May 2023 | 1,389 | 200,894 (0%) | 0% | 2.0 | 2,750 | Common Stock |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Lonnie Shoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 17 May 2023 | 1,781 | 81,627 (0%) | 0% | 2.0 | 3,526 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 17 May 2023 | 971 | 130,346 (0%) | 0% | 2.0 | 1,923 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 2.29 per share. | 02 May 2023 | 5,102 | 83,408 (0%) | 0% | 2.3 | 11,684 | Common Stock |
| Aaron L. Tachibana | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.83 per share. | 17 Mar 2023 | 3,945 | 202,283 (0%) | 0% | 2.8 | 11,164 | Common Stock |
| Richard Chen | Chief Medical Officer and EVP | Sale of securities on an exchange or to another person at price $ 2.83 per share. | 17 Mar 2023 | 1,314 | 131,317 (0%) | 0% | 2.8 | 3,719 | Common Stock |
| Aaron L. Tachibana | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Christopher Hall | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Medical Officer and EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.20 per share. | 31 Jan 2023 | 767 | 206,228 (0%) | 0% | 2.2 | 1,687 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.20 per share. | 31 Jan 2023 | 562 | 132,631 (0%) | 0% | 2.2 | 1,236 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.92 per share. | 20 Dec 2022 | 3,843 | 206,995 (0%) | 0% | 1.9 | 7,379 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.92 per share. | 20 Dec 2022 | 1,750 | 133,193 (0%) | 0% | 1.9 | 3,360 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 15 Dec 2022 | 7,177 | 210,838 (0%) | 0% | 2.5 | 17,943 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 15 Dec 2022 | 1,930 | 88,510 (0%) | 0% | 2.5 | 4,825 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 15 Dec 2022 | 7,177 | 134,943 (0%) | 0% | 2.5 | 17,943 | Common Stock |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2022 | 10,000 | 239,999 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.44 per share. | 14 Dec 2022 | 10,000 | 622,444 (1%) | 0% | 2.4 | 24,400 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 02 Dec 2022 | 4,360 | 218,015 (0%) | 0% | 2.6 | 11,336 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 02 Dec 2022 | 440 | 142,120 (0%) | 0% | 2.6 | 1,144 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 16 Nov 2022 | 1,294 | 222,375 (0%) | 0% | 2.7 | 3,507 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 16 Nov 2022 | 2,045 | 90,440 (0%) | 0% | 2.7 | 5,542 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 16 Nov 2022 | 1,295 | 142,560 (0%) | 0% | 2.7 | 3,509 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.48 per share. | 20 Sep 2022 | 3,474 | 223,669 (0%) | 0% | 3.5 | 12,090 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.48 per share. | 20 Sep 2022 | 1,581 | 143,855 (0%) | 0% | 3.5 | 5,502 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.33 per share. | 02 Sep 2022 | 4,168 | 227,143 (0%) | 0% | 3.3 | 13,879 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.33 per share. | 02 Sep 2022 | 420 | 145,436 (0%) | 0% | 3.3 | 1,399 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 29,890 | 29,890 | - | - | Stock Option (right to buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 230,000 | 612,444 (1%) | 0% | 0 | Common Stock | |
| Stephen M. Moore | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 28,700 | 28,700 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 18,600 | 92,485 (0%) | 0% | 0 | Common Stock | |
| Stephen M. Moore | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 28,700 | 28,700 | - | - | Stock Option (right to buy) | |
| Stephen M. Moore | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 18,600 | 92,485 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 29,890 | 29,890 | - | - | Stock Option (right to buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.91 per share. | 28 Jul 2022 | 632 | 231,311 (0%) | 0% | 3.9 | 2,471 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.91 per share. | 28 Jul 2022 | 632 | 145,856 (0%) | 0% | 3.9 | 2,471 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.29 per share. | 17 Jun 2022 | 3,440 | 231,943 (0%) | 0% | 3.3 | 11,318 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.29 per share. | 17 Jun 2022 | 1,565 | 146,488 (0%) | 0% | 3.3 | 5,149 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.24 per share. | 15 Jun 2022 | 6,818 | 235,383 (0%) | 0% | 3.2 | 22,090 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 3.24 per share. | 15 Jun 2022 | 1,832 | 73,885 (0%) | 0% | 3.2 | 5,936 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.24 per share. | 15 Jun 2022 | 6,818 | 148,053 (0%) | 0% | 3.2 | 22,090 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.59 per share. | 02 Jun 2022 | 4,187 | 242,201 (0%) | 0% | 3.6 | 15,031 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.59 per share. | 02 Jun 2022 | 421 | 154,871 (0%) | 0% | 3.6 | 1,511 | Common Stock |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 13,506 (0%) | 0% | 0 | Common Stock | |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 43,506 (0%) | 0% | 0 | Common Stock | |
| Kenneth E. Ludlum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 13,506 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 16,116 (0%) | 0% | 0 | Common Stock | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 13,506 (0%) | 0% | 0 | Common Stock | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 21,015 (0%) | 0% | 0 | Common Stock | |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 16 May 2022 | 1,286 | 246,388 (0%) | 0% | 4.9 | 6,250 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 16 May 2022 | 2,408 | 382,444 (1%) | 0% | 4.9 | 11,703 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 16 May 2022 | 664 | 75,717 (0%) | 0% | 4.9 | 3,227 | Common Stock |
| Richard Chen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 4.76 per share. | 16 May 2022 | 1,558 | 157,116 (0%) | 0% | 4.8 | 7,416 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 16 May 2022 | 1,286 | 155,830 (0%) | 0% | 4.9 | 6,250 | Common Stock |
| Stephen M. Moore | General Counsel | Sale of securities on an exchange or to another person at price $ 5.53 per share. | 02 May 2022 | 5,733 | 76,381 (0%) | 0% | 5.5 | 31,703 | Common Stock |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 45,061 | 0 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.84 per share. | 20 Apr 2022 | 45,061 | 384,852 (1%) | 0% | 1.8 | 82,912 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Apr 2022 | 64,430 | 0 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Apr 2022 | 64,430 | 339,791 (1%) | 0% | - | Common Stock | |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.84 per share. | 13 Apr 2022 | 64,430 | 404,221 (1%) | 0% | 1.8 | 118,551 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 7.98 per share. | 17 Mar 2022 | 3,767 | 247,674 (0%) | 0% | 8.0 | 30,061 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.84 per share. | 17 Mar 2022 | 54,347 | 339,804 (1%) | 0% | 1.8 | 99,998 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 17 Mar 2022 | 54,347 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 7.98 per share. | 17 Mar 2022 | 1,776 | 155,558 (0%) | 0% | 8.0 | 14,172 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 7.47 per share. | 14 Mar 2022 | 68,162 | 285,457 (0%) | 0% | 7.5 | 509,170 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Mar 2022 | 68,162 | 54,346 | - | - | Common Stock (Right to Buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.84 per share. | 14 Mar 2022 | 68,162 | 353,619 (1%) | 0% | 1.8 | 125,418 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 8.15 per share. | 14 Mar 2022 | 21,206 | 285,457 (0%) | 0% | 8.2 | 172,829 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.84 per share. | 14 Mar 2022 | 21,206 | 306,663 (0%) | 0% | 1.8 | 39,019 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Mar 2022 | 21,206 | 122,508 | - | - | Common Stock (Right to Buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.84 per share. | 10 Mar 2022 | 32,897 | 318,354 (1%) | 0% | 1.8 | 60,530 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 8.99 per share. | 10 Mar 2022 | 10,888 | 285,457 (0%) | 0% | 9.0 | 97,883 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.84 per share. | 10 Mar 2022 | 10,888 | 296,339 (0%) | 0% | 1.8 | 20,034 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 9.38 per share. | 10 Mar 2022 | 32,897 | 285,457 (0%) | 0% | 9.4 | 308,574 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.18 per share. | 02 Mar 2022 | 4,511 | 251,441 (0%) | 0% | 10.2 | 45,922 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.18 per share. | 02 Mar 2022 | 471 | 157,334 (0%) | 0% | 10.2 | 4,795 | Common Stock |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 15,691 | 15,691 | - | - | Stock Option (Right to Buy) | |
| Olivia Bloom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 10,245 | 10,245 (0%) | 0% | 0 | Common Stock | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.93 per share. | 28 Jan 2022 | 705 | 255,952 (0%) | 0% | 9.9 | 7,001 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.93 per share. | 28 Jan 2022 | 705 | 157,805 (0%) | 0% | 9.9 | 7,001 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.01 per share. | 18 Jan 2022 | 64,503 | 285,457 (0%) | 0% | 11.0 | 710,178 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.73 per share. | 18 Jan 2022 | 35,484 | 349,960 (1%) | 0% | 11.7 | 416,227 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 17 Dec 2021 | 3,437 | 256,657 (0%) | 0% | 12.8 | 43,994 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 17 Dec 2021 | 2,732 | 385,444 (1%) | 0% | 12.8 | 34,970 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 17 Dec 2021 | 1,563 | 158,510 (0%) | 0% | 12.8 | 20,006 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 80,000 | 260,094 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 80,000 | 160,073 (0%) | 0% | 0 | Common Stock | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.92 per share. | 02 Dec 2021 | 4,184 | 180,094 (0%) | 0% | 12.9 | 54,057 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.92 per share. | 02 Dec 2021 | 419 | 80,073 (0%) | 0% | 12.9 | 5,413 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.65 per share. | 30 Nov 2021 | 100,000 | 485,444 (1%) | 0% | 13.7 | 1,365,000 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 17 Nov 2021 | 1,253 | 184,278 (0%) | 0% | 17.0 | 21,351 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 17 Nov 2021 | 2,348 | 585,444 (1%) | 0% | 17.0 | 40,010 | Common Stock |
| Richard Chen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 17 Nov 2021 | 1,253 | 79,781 (0%) | 0% | 17.0 | 21,351 | Common Stock |
| Richard Chen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 16.68 per share. | 17 Nov 2021 | 711 | 80,492 (0%) | 0% | 16.7 | 11,859 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.33 per share. | 12 Oct 2021 | 100,000 | 587,792 (1%) | 0% | 19.3 | 1,933,000 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.25 per share. | 17 Sep 2021 | 3,152 | 185,531 (0%) | 0% | 21.3 | 66,980 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.25 per share. | 17 Sep 2021 | 1,088 | 81,034 (0%) | 0% | 21.3 | 23,120 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 22.28 per share. | 14 Sep 2021 | 6,600 | 687,792 (2%) | 0% | 22.3 | 147,048 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 21.65 per share. | 14 Sep 2021 | 93,400 | 694,392 (2%) | 0% | 21.7 | 2,022,110 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 02 Sep 2021 | 3,820 | 188,683 (0%) | 0% | 21.9 | 83,734 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 02 Sep 2021 | 291 | 82,122 (0%) | 0% | 21.9 | 6,379 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 26 Aug 2021 | 77,272 | 787,792 (2%) | 0% | 0.4 | 34,000 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Aug 2021 | 77,272 | 0 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 16.81 per share. | 19 Aug 2021 | 115,228 | 710,520 (2%) | 0% | 16.8 | 1,936,983 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 19 Aug 2021 | 115,228 | 825,748 (2%) | 0% | 0.4 | 50,700 | Common Stock |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2021 | 115,228 | 77,271 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.22 per share. | 06 Aug 2021 | 4,436 | 82,413 (0%) | 0% | 21.2 | 94,132 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 15,564 | 102,413 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.18 per share. | 06 Aug 2021 | 15,564 | 86,849 (0%) | 0% | 21.2 | 329,646 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 5,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 9,618 | 44,728 | - | - | Stock Option (Right to Buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 10,000 | 192,503 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 10,000 | 84,980 (0%) | 0% | 0 | Common Stock | |
| John West | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jul 2021 | 75,000 | 192,499 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 15 Jul 2021 | 75,000 | 710,520 (2%) | 0% | 0.4 | 33,000 | Common Stock |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 08 Jul 2021 | 110,000 | 745,520 (2%) | 0% | 0.4 | 48,400 | Common Stock |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 110,000 | 267,499 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.54 per share. | 08 Jul 2021 | 110,000 | 635,520 (2%) | 0% | 22.5 | 2,479,400 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 17 Jun 2021 | 2,421 | 182,503 (0%) | 0% | 22.8 | 55,078 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 17 Jun 2021 | 1,101 | 74,980 (0%) | 0% | 22.8 | 25,048 | Common Stock |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 75,000 | 377,499 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 15 Jun 2021 | 75,000 | 635,520 (2%) | 0% | 0.4 | 33,000 | Common Stock |
| John West | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 110,000 | 452,499 | - | - | Stock Option (Right to Buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.44 per share. | 08 Jun 2021 | 110,000 | 670,520 (2%) | 0% | 0.4 | 48,400 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.38 per share. | 08 Jun 2021 | 100,050 | 570,470 (1%) | 0% | 22.4 | 2,239,119 | Common Stock |
| John West | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.93 per share. | 08 Jun 2021 | 9,950 | 560,520 (1%) | 0% | 22.9 | 228,154 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.57 per share. | 02 Jun 2021 | 2,899 | 184,924 (0%) | 0% | 21.6 | 62,531 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.57 per share. | 02 Jun 2021 | 291 | 76,081 (0%) | 0% | 21.6 | 6,277 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 20,000 | 187,823 (0%) | 0% | 0 | Common Stock | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 53,750 | 560,520 (1%) | 0% | 0 | Common Stock | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 107,500 | 107,500 | - | - | Stock Option (right to buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 20,000 | 76,372 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 2,736 (0%) | 0% | 0 | Common Stock | |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 32,736 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 2,736 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 5,346 (0%) | 0% | 0 | Common Stock | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 2,736 (0%) | 0% | 0 | Common Stock | |
| Jonathan James MacQuitty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 2,736 (0%) | 0% | 0 | Common Stock | |
| Jonathan James MacQuitty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.96 per share. | 01 Apr 2021 | 6,260 | 55,834 (0%) | 0% | 26.0 | 162,510 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 12,517 | 5,945 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.69 per share. | 01 Apr 2021 | 12,517 | 55,834 (0%) | 0% | 25.7 | 321,562 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 01 Apr 2021 | 12,517 | 68,351 (0%) | 0% | 0.4 | 5,507 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.61 per share. | 01 Apr 2021 | 21,223 | 62,094 (0%) | 0% | 25.6 | 543,521 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.73 per share. | 17 Mar 2021 | 2,446 | 167,823 (0%) | 0% | 26.7 | 65,382 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.73 per share. | 17 Mar 2021 | 1,130 | 83,317 (0%) | 0% | 26.7 | 30,205 | Common Stock |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2021 | 3,719 | 3,719 | - | - | Stock Option (Right to Buy) | |
| Woodrow A. Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2021 | 2,610 | 2,610 (0%) | 0% | 0 | Common Stock | |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 02 Mar 2021 | 3,022 | 170,269 (0%) | 0% | 32.6 | 98,517 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 02 Mar 2021 | 345 | 84,447 (0%) | 0% | 32.6 | 11,247 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 01 Feb 2021 | 20,059 | 84,792 (0%) | 0% | 38.8 | 778,891 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 13,422 | 18,462 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.80 per share. | 01 Feb 2021 | 11,022 | 84,792 (0%) | 0% | 38.8 | 427,654 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.12 per share. | 01 Feb 2021 | 2,400 | 95,814 (0%) | 0% | 38.1 | 91,488 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 01 Feb 2021 | 13,422 | 98,214 (0%) | 0% | 0.4 | 5,906 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.19 per share. | 01 Feb 2021 | 6,519 | 104,851 (0%) | 0% | 38.2 | 248,961 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.37 per share. | 17 Dec 2020 | 2,391 | 173,291 (0%) | 0% | 36.4 | 86,961 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.37 per share. | 17 Dec 2020 | 1,087 | 111,370 (0%) | 0% | 36.4 | 39,534 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 01 Dec 2020 | 2,926 | 175,682 (0%) | 0% | 27.8 | 81,226 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 40,000 | 31,884 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 01 Dec 2020 | 293 | 112,457 (0%) | 0% | 27.8 | 8,134 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.14 per share. | 01 Dec 2020 | 25,612 | 112,750 (0%) | 0% | 28.1 | 720,722 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.75 per share. | 01 Dec 2020 | 14,388 | 138,362 (0%) | 0% | 27.8 | 399,267 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 01 Dec 2020 | 40,000 | 152,750 (0%) | 0% | 0.4 | 17,600 | Common Stock |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.67 per share. | 01 Oct 2020 | 13,472 | 139,278 (0%) | 0% | 21.7 | 291,938 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 37,452 | 71,884 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 01 Oct 2020 | 26,528 | 112,750 (0%) | 0% | 22.3 | 590,513 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 01 Oct 2020 | 37,452 | 152,750 (0%) | 0% | 0.4 | 16,479 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.74 per share. | 17 Sep 2020 | 2,463 | 178,608 (0%) | 0% | 22.7 | 56,009 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.74 per share. | 17 Sep 2020 | 1,120 | 115,298 (0%) | 0% | 22.7 | 25,469 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 02 Sep 2020 | 2,899 | 181,071 (0%) | 0% | 23.0 | 66,648 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 02 Sep 2020 | 291 | 116,418 (0%) | 0% | 23.0 | 6,690 | Common Stock |
| Kenneth E. Ludlum | Director | Sale of securities on an exchange or to another person at price $ 20.42 per share. | 14 Aug 2020 | 6,470 | 30,000 (0%) | 0% | 20.4 | 132,117 | Common Stock |
| Kenneth E. Ludlum | Director | Sale of securities on an exchange or to another person at price $ 20.05 per share. | 14 Aug 2020 | 13,530 | 36,470 (0%) | 0% | 20.1 | 271,277 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.47 per share. | 14 Aug 2020 | 1,200 | 116,709 (0%) | 0% | 20.5 | 24,564 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.17 per share. | 14 Aug 2020 | 27,366 | 117,909 (0%) | 0% | 20.2 | 551,972 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.76 per share. | 14 Aug 2020 | 3,434 | 145,275 (0%) | 0% | 19.8 | 67,856 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2020 | 28,566 | 148,709 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2020 | 653 | 54,346 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2020 | 27,913 | 109,336 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.37 per share. | 22 Jun 2020 | 1,085 | 120,143 (0%) | 0% | 12.4 | 13,421 | Common Stock |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.34 per share. | 05 Jun 2020 | 272 | 121,228 (0%) | 0% | 14.3 | 3,900 | Common Stock |
| A. Blaine Bowman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Alan B. Colowick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Patrick J. Balthrop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Paul A. Ricci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Jonathan James MacQuitty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2020 | 15,000 | 121,500 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2020 | 15,000 | 137,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2020 | 10,000 | 152,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2020 | 10,000 | 106,500 (0%) | 0% | 0 | Common Stock | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2020 | 421,000 | 421,000 | - | - | Stock Option (right to buy) | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2020 | 330,000 | 330,000 | - | - | Stock Option (right to buy) | |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 82,500 | 183,970 (0%) | 0% | 0 | Common Stock | |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 82,500 | 183,970 (0%) | 0% | 0 | Common Stock | |
| Clinton Musil | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 11,000 | 11,000 | - | - | Common Stock (right to Buy) | |
| Clinton Musil | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 11,000 | 11,000 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 37,500 | 96,500 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2020 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.84 per share. | 09 Mar 2020 | 1,000 | 59,000 (0%) | 0% | 7.8 | 7,840 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2020 | 1,000 | 162,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2020 | 1,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.77 per share. | 25 Feb 2020 | 101,000 | 59,000 (0%) | 0% | 8.8 | 885,770 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2020 | 101,000 | 164,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2020 | 101,000 | 160,000 (0%) | 0% | 0 | Common Stock | |
| Kenneth E. Ludlum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2020 | 4,167 | 0 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 07 Feb 2020 | 4,167 | 50,000 (0%) | 0% | 3.8 | 15,835 | Common Stock |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2020 | 12,000 | 265,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 07 Jan 2020 | 12,000 | 59,000 (0%) | 0% | 0.4 | 5,280 | Common Stock |
| Paul A. Ricci | Director | 31 Dec 2019 | 1 | 19,999 (0%) | 0% | 10 | 10 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 12,000 | 277,249 | - | - | Stock Option (right to buy) | |
| Richard Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.44 per share. | 20 Dec 2019 | 12,000 | 47,000 (0%) | 0% | 0.4 | 5,280 | Common Stock |
| Aaron L. Tachibana | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2019 | 100,000 | 102,249 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2019 | 10,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Richard Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2019 | 10,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| John West | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 8.65 per share. | 22 Nov 2019 | 3,000 | 505,412 (1%) | 0% | 8.7 | 25,952 | Common Stock |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2019 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Kenneth E. Ludlum | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 24 Jun 2019 | 70,000 | 70,000 (0%) | 0% | 17 | 1,190,000 | Common Stock |
| Paul A. Ricci | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 24 Jun 2019 | 20,000 | 20,000 (0%) | 0% | 17 | 340,000 | Common Stock |
| Paul A. Ricci | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 24 Jun 2019 | 20,000 | 20,000 (0%) | 0% | 17 | 340,000 | Common Stock |